CN Bio to provide drug metabolism and safety toxicity testing services
CN Bio, a leading 3D cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services.
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, has announced a collaboration with Imperial College London, a world-class research university. The research will harness CN Bio’s Liver-on-Chip technology to advance the understanding of the underlying mechanisms of alcoholic…
CN Bio makes key senior appointments to support international commercial development
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the appointments of James Craven as Chief Commercial Officer and Dr Brian Manning as US Head of Sales.
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism1, identifying a novel pathway that regulates the underlying mechanism of Non-Alcoholic…
CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
CN Bio Innovations (CN Bio), a leading cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, today announced it has raised $9 million USD (circa £6.9 million GBP) investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations Holdings Ltd.